Indaptus Therapeutics Stock Price To Earnings To Growth
| INDP Stock | USD 7.30 0.86 10.54% |
Indaptus Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Indaptus Stock price.
Indaptus | Price To Earnings To Growth | Build AI portfolio with Indaptus Stock |
Indaptus Therapeutics Company Price To Earnings To Growth Analysis
Indaptus Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Indaptus Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Indaptus Therapeutics is extremely important. It helps to project a fair market value of Indaptus Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Indaptus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Indaptus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Indaptus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Indaptus Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Indaptus Therapeutics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Indaptus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Indaptus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Indaptus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Indaptus Fundamentals
| Return On Equity | -2.59 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 348.89 K | ||||
| Shares Outstanding | 572.66 K | ||||
| Shares Owned By Insiders | 19.42 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 14.72 K | ||||
| Price To Book | 1.49 X | ||||
| EBITDA | (15.02 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 4.89 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (41.44) X | ||||
| Target Price | 56.0 | ||||
| Beta | 1.15 | ||||
| Market Capitalization | 4.18 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
| Net Asset | 7.34 M |
About Indaptus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indaptus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.